Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon
المجلة: International Journal of Hematology | عدد الاستشهادات على Scopus: 0
اقرأ المزيد ←